The third variable loop area (V3 loop) on gp120 performs an necessary position in mobile entry of HIV-1. Its interplay with the mobile CD4 and coreceptors is a crucial hallmark in facilitating the bridging by gp41 and subsequent fusion of membranes for switch of viral genetic materials. Additional, the virus phenotype determines the cell tropism by way of respective co- receptor binding.
Thus, coreceptor binding motif of envelope is taken into account to be a potent anti-viral drug goal for viral entry inhibition. Nonetheless, its excessive variability in sequence is the foremost hurdle for creating inhibitors concentrating on the area. On this examine, we have now used an in silico Digital Screening and “Fragment-based” methodology to design small molecules primarily based on the gp120 V3 loop interactions with a potent broadly neutralizing human monoclonal antibody, 447-52D.
From the in silico evaluation a potent scaffold, 1,3,5-triazine was recognized for additional growth. Derivatives of 1,3,5-triazine with particular useful teams have been designed and synthesized conserving the interplay with co-receptor intact. Lastly, preliminary analysis of molecules for HIV-1 inhibition on two completely different virus strains (clade C, clade B) yielded IC50 < 5.zero μM.
The method used to design molecules primarily based on broadly neutralizing antibody, was helpful for growth of goal particular potent antiviral brokers to forestall HIV entry. The examine reported promising inhibitors that might be additional developed and studied.
Cytokine antibody array-based evaluation of IL-37 therapy results in bronchial asthma
Bronchial asthma is pushed by group 2 innate lymphoid cells, antigen-specific CD4+ T helper sort 2 cells and their cytokines corresponding to interleukin (IL)-4, IL-5, IL-13. IL-37 is decreased in bronchial asthma and negatively associated to Th2 cytokines and different pro-inflammatory cytokines. Our examine confirmed that IL-37 degree in asthmatic peripheral blood mononuclear cells was decrease than in wholesome.
Additional, IL-37 was negatively correlated with exhaled nitric oxide, bronchial asthma management take a look at rating, atopy and rhinitis historical past in asthmatics. Then an OVA-induced bronchial asthma mice mannequin handled with rhIL-37 was established.
An antibody array was employed to uncover altered cytokines induced by IL-37 in mice lung tissue. 20 proteins differentially expressed after rhIL-37 therapy and 5 of them have been validated in asthmatic peripheral blood mononuclear cells. According to cytokine antibody array, CCL3, CCL4, CCL5 decreased after IL-37 administration. Whereas CXCL9 and CXCL13 have been no change. We concluded that IL-37 scale back asthmatic signs by inhibit pro-inflammatory cytokine corresponding to CCL3, CCL4, CCL5.
Editorial: The First Monoclonal Antibody Vaccine to Forestall Malaria Heralds a New Period of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP)
Malaria impacts greater than Three billion individuals in 95 nations, with an estimated mortality charge of 400,000 per 12 months. The feminine Anopheles spp mosquito mostly transmits malaria, and the primary burden of illness is because of Plasmodium falciparum. Essentially the most ample antigen on the sporozoite floor is the Plasmodium falciparum circumsporozoite protein (PfCSP).
PfCSP is required for parasite growth and attachment to host hepatocytes. The primary potential protein vaccine, RTS,S/ASO1, consists of a recombinant fusion antigen primarily based on PfCSP. Preliminary findings from a part Three trial of RTS,S/ASO1 have been promising however resulted in suggestions for additional analysis in large-scale trials. R21, a circumsporozoite protein-based vaccine, mixed with an adjuvant, Matrix-M (MM), was lately evaluated in a part 2 investigational examine in kids between 5-17 months of age in Burkina Faso.
The R21/MM candidate vaccine resulted in excessive titers of malaria-specific antibodies. On August 26, 2021, the findings from a part 1 trial on a brand new monoclonal antibody to PfCSP, CIS43LS, confirmed {that a} single dose of the CIS43LS monoclonal antibody resulted in safety towards malaria.
These new findings have implications for the seasonal management of malaria in endemic areas and a potential future position in public well being methods to get rid of malaria. This Editorial goals to supply the background to creating and evaluating the brand new malaria vaccines that focus on PfCSP, together with the primary monoclonal antibody vaccine to malaria.
Characterization and modulation of anti-αβTCR antibodies and their respective binding websites on the βTCR chain to complement engineered T cells
T cell engineering methods provide cures to sufferers and have entered scientific observe with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based methods are, nonetheless, lagging behind. To permit a extra speedy and profitable translation to profitable ideas additionally utilizing αβTCRs for engineering, incorporating a technique for the purification of genetically modified T cells, in addition to engineered T cell deletion after switch into sufferers, might be useful.
This might enable elevated efficacy, lowered potential unwanted side effects, and improved security of newly to-be-tested lead constructions. By characterizing the antigen-binding interface of a great manufacturing course of (GMP)-grade anti-αβTCR antibody, normally used for depletion of αβT cells from stem cell transplantation merchandise, we developed a method that permits for the purification of untouched αβTCR-engineered immune cells by altering 2 amino acids solely within the TCRβ chain fixed area of launched TCR chains.
Alternatively, we engineered an antibody that targets an prolonged mutated interface of 9 amino acids within the TCRβ chain fixed area and gives the chance to additional develop depletion methods of engineered immune cells.

Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Affected person as a Software to Research Autoimmune Seizures
Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis manifests with precipitous cognitive decline, irregular actions, and extreme seizures that may be difficult to manage with typical anti-seizure drugs. We beforehand demonstrated that intracerebroventricular (i.c.v.) administration of cerebrospinal fluid from affected sufferers, or purified NMDA receptor antibodies from encephalitis sufferers to mice precipitated seizures, thereby confirming that antibodies are straight pathogenic for seizures.
Though completely different repertoires of anti-NMDA receptor antibodies might contribute to the distinct scientific manifestations in encephalitis sufferers, the position of particular antibodies within the expression of seizure, motor, and cognitive phenotypes stays unclear. Utilizing three completely different patient-derived monoclonal antibodies with distinct epitopes throughout the N-terminal area (NTD) of the NMDA receptor, we characterised the seizure burden, motor exercise and anxiety-related conduct in mice.
We discovered that steady administration of 5F5, 2G6 or 3C11 antibodies for two weeks precipitated seizures, as measured with steady EEG utilizing cortical screw electrodes. The seizure burden was comparable in all three antibody-treated teams. The seizures have been accompanied by elevated hippocampal C-C chemokine ligand 2 (CCL2) mRNA expression Three days after antibody infusion had stopped.
Anti-PD-L1 Antibody |
A1454-100 |
Biovision |
each |
EUR 405.6 |
Anti-PD-L1 Antibody |
A1454-30T |
Biovision |
each |
EUR 175.2 |
Anti-PD-L1 antibody |
STJ190082 |
St John's Laboratory |
200 µl |
EUR 236.4 |
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7) |
Anti-PD-L1 antibody |
STJ130022 |
St John's Laboratory |
50 µl |
EUR 385.2 |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
Anti-PD-L1 antibody |
STJ130023 |
St John's Laboratory |
50 µl |
EUR 385.2 |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
Anti-PD-L1 antibody |
STJ130024 |
St John's Laboratory |
50 µl |
EUR 385.2 |
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies. |
anti- PD-L1/CD274 antibody |
FNab06280 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against PD-L1/CD274 |
anti- PD-L1/CD274 antibody |
FNab06281 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against PD-L1/CD274 |
anti-PD-L1 VHH antibody |
JOT0002-5 |
Jotbody |
each |
Ask for price |
Anti-PD-L1/CD274 Antibody |
PB9994 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1/CD274 Antibody |
PB9154 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1/CD274 Antibody |
PA1851 |
BosterBio |
100ug/vial |
EUR 352.8 |
Anti-PD-L1 Antibody (IHC411) |
A1549-50 |
Biovision |
each |
EUR 222 |
Anti-PD-L1, PE-labeled |
71128-1 |
BPS Bioscience |
50 µg |
EUR 355 |
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species. |
Anti-PD-L1, PE-labeled |
71128-2 |
BPS Bioscience |
100 µg |
EUR 510 |
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species. |
PD-L1 Antibody |
4059-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
PD-L1 Antibody |
4059-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
PD-L1 Antibody |
49251-100ul |
SAB |
100ul |
EUR 399.6 |
PD-L1 Antibody |
49251-50ul |
SAB |
50ul |
EUR 286.8 |
PD-L1 Antibody |
P1013-01m |
SAB |
0.1m |
EUR 224.4 |
PD-L1 Antibody |
P1013-1ml |
SAB |
1ml |
EUR 807.6 |
PD-L1 Antibody |
R31573 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: Programmed death-ligand 1, also known as CD274 or B7-H1 is a protein that in humans is encoded by the CD274 gene. It is a 33-70kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. Upregulation on tumor MDCs downregulates T-cell immunity and PD-L1 blockade may represent an approach for cancer immunotherapy. It can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. It has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer. |
PD-L1 Antibody |
R33263-100UG |
NSJ Bioreagents |
100 ug |
EUR 339.15 |
Description: Additional name(s) for this target protein: Programmed cell death 1 ligand 1; CD274 |
Anti-PD-L1 (CD274) Neutralizing Antibody |
71213 |
BPS Bioscience |
100 µg |
EUR 505 |
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested. |
Anti-PD-L1 (Atezolizumab), humanized Antibody |
A1305-100 |
Biovision |
each |
EUR 601.2 |
PD-L1 Antibody [F6A9] |
SD8639-002mg |
ProSci |
0.02 mg |
EUR 253.22 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
PD-L1 Antibody [F6A9] |
SD8639-01mg |
ProSci |
0.1 mg |
EUR 723.62 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
PD-L1 Antibody [F2G2] |
SD8641-002mg |
ProSci |
0.02 mg |
EUR 253.22 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
PD-L1 Antibody [F2G2] |
SD8641-01mg |
ProSci |
0.1 mg |
EUR 723.62 |
|
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. |
Mouse PD-L1 Antibody |
32903-05111 |
AssayPro |
150 ug |
EUR 313.2 |
PD-L1 Protein |
20-abx261703 |
Abbexa |
-
EUR 4101.60
-
EUR 393.60
-
EUR 276.00
|
|
|
PD-L1 Protein |
20-abx263458 |
Abbexa |
-
EUR 1930.80
-
EUR 393.60
-
EUR 276.00
|
|
|
PD-L1 (CD274) |
100443-1 |
BPS Bioscience |
100 µg |
EUR 320 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
PD-L1 (CD274) |
100443-2 |
BPS Bioscience |
1 mg |
EUR 2720 |
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa. |
PD-L1 Peptide |
4059P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) PD-L1 peptide |
PD-L1 Peptide |
46-156P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: CD274 / PD-L1 Peptide |
PD-L1, CD274 |
E6TA00108 |
EnoGene |
0.1mg |
EUR 411.6 |
PD-L1 Conjugated Antibody |
C49251 |
SAB |
100ul |
EUR 476.4 |
Anti-PD-L1/B7-H1/CD274 Antibody |
A00109 |
BosterBio |
100ug/vial |
EUR 352.8 |
PE Anti-Mouse CD274/PD-L1 Antibody |
DL21657F-20Tests |
DL Develop |
20Tests |
EUR 152 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE Anti-Mouse CD274/PD-L1 Antibody |
DL21657F-50Tests |
DL Develop |
50Tests |
EUR 207.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE Anti-Mouse CD274/PD-L1 Antibody |
DL21660F-25ug |
DL Develop |
25μg |
EUR 200 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE Anti-Mouse CD274/PD-L1 Antibody |
DL21660F-50ug |
DL Develop |
50μg |
EUR 282.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE Anti-Human CD274/PD-L1 Antibody |
DL21667F-20Tests |
DL Develop |
20Tests |
EUR 192.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
PE Anti-Human CD274/PD-L1 Antibody |
DL21667F-50Tests |
DL Develop |
50Tests |
EUR 267.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
APC Anti-Mouse CD274/PD-L1 Antibody |
DL21658F-20Tests |
DL Develop |
20Tests |
EUR 162.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
APC Anti-Mouse CD274/PD-L1 Antibody |
DL21658F-50Tests |
DL Develop |
50Tests |
EUR 222.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
APC Anti-Mouse CD274/PD-L1 Antibody |
DL21661F-25ug |
DL Develop |
25μg |
EUR 200 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
APC Anti-Mouse CD274/PD-L1 Antibody |
DL21661F-50ug |
DL Develop |
50μg |
EUR 305 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
APC Anti-Human CD274/PD-L1 Antibody |
DL21668F-20Tests |
DL Develop |
20Tests |
EUR 192.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
APC Anti-Human CD274/PD-L1 Antibody |
DL21668F-50Tests |
DL Develop |
50Tests |
EUR 267.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
FITC Anti-Human CD274/PD-L1 Antibody |
DL21666F-20Tests |
DL Develop |
20Tests |
EUR 192.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
FITC Anti-Human CD274/PD-L1 Antibody |
DL21666F-50Tests |
DL Develop |
50Tests |
EUR 267.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Biotin Anti-Mouse CD274/PD-L1 Antibody |
DL21656F-100ug |
DL Develop |
100μg |
EUR 297.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
Biotin Anti-Mouse CD274/PD-L1 Antibody |
DL21656F-50ug |
DL Develop |
50μg |
EUR 215 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
Biotin Anti-Human CD274/PD-L1 Antibody |
DL21665F-100ug |
DL Develop |
100μg |
EUR 320 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Biotin Anti-Human CD274/PD-L1 Antibody |
DL21665F-25ug |
DL Develop |
25μg |
EUR 170 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Anti-PD-L1 (Avelumab), Human IgG1 Antibody |
A2152-100 |
Biovision |
100 µg |
EUR 612 |
Purified Anti-Mouse CD274/PD-L1 Antibody |
DL21655F-100ug |
DL Develop |
100μg |
EUR 230 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
Purified Anti-Mouse CD274/PD-L1 Antibody |
DL21655F-50ug |
DL Develop |
50μg |
EUR 170 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
Purified Anti-Human CD274/PD-L1 Antibody |
DL21664F-100ug |
DL Develop |
100μg |
EUR 275 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Purified Anti-Human CD274/PD-L1 Antibody |
DL21664F-25ug |
DL Develop |
25μg |
EUR 155 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Polyclonal Goat Anti-CD274 / PD-L1 Antibody |
APG00067G |
Leading Biology |
0.1mg |
EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CD274 / PD-L1 . This antibody is tested and proven to work in the following applications: |
Anti-PD-L1 (Durvalumab), Human IgG1 Antibody |
A2109-100 |
Biovision |
100 µg |
EUR 612 |
Anti-PD-L1 (CD274) Rabbit Monoclonal Antibody |
M00109 |
BosterBio |
100ug/vial |
EUR 476.4 |
Description: Rabbit Monoclonal PD-L1 (CD274) Antibody. Validated in IHC-P, WB and tested in Human, Mouse, Rat. |
Anti-PD-L1 Monoclonal Antibody (Clone: ABM5F25) |
A1537-50 |
Biovision |
each |
EUR 366 |
Anti-PD-L1 Neutralizing Antibody, Biotin-labeled |
71214 |
BPS Bioscience |
100 µg |
EUR 510 |
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species. |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM025-100ug |
SAB |
100ug |
EUR 337.2 |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM025-25ug |
SAB |
25ug |
EUR 198 |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM026-100ug |
SAB |
100ug |
EUR 337.2 |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM026-25ug |
SAB |
25ug |
EUR 198 |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM027-100ug |
SAB |
100ug |
EUR 267.6 |
Mouse Anti-Human CD274 (PD-L1) mAb |
CM027-25ug |
SAB |
25ug |
EUR 181.2 |
Mouse Anti-Human CD274 (PD-L1) mAb |
P1062-25ug |
SAB |
25ug |
EUR 181.2 |
PD-1/PD-L1 Inhibitor 2 |
B1050-25 |
Biovision |
each |
EUR 679.2 |
PD-1/PD-L1 Inhibitor 2 |
B1050-5 |
Biovision |
each |
EUR 242.4 |
PD-1/PD-L1 Inhibitor 1 |
B1213-25 |
Biovision |
each |
EUR 679.2 |
PD-1/PD-L1 inhibitor 2 |
B6023-25 |
ApexBio |
25 mg |
EUR 525.6 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 inhibitor 2 |
B6023-5 |
ApexBio |
5 mg |
EUR 205.2 |
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor. |
PD-1/PD-L1 inhibitor 1 |
B6172-25 |
ApexBio |
25 mg |
EUR 543.6 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
PD-1/PD-L1 inhibitor 1 |
B6172-5 |
ApexBio |
5 mg |
EUR 201.6 |
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems. |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody |
20-abx319445 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ribosome-inactivating protein PD-L1/PD-L2 Antibody |
1-CSB-PA306294LA01PJJ |
Cusabio |
|
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA |
PD-L1 Rabbit pAb |
A11273-100ul |
Abclonal |
100 ul |
EUR 369.6 |
PD-L1 Rabbit pAb |
A11273-200ul |
Abclonal |
200 ul |
EUR 550.8 |
PD-L1 Rabbit pAb |
A11273-20ul |
Abclonal |
20 ul |
EUR 219.6 |
PD-L1 Rabbit pAb |
A11273-50ul |
Abclonal |
50 ul |
EUR 267.6 |
PD-L1 Rabbit pAb |
A1645-100ul |
Abclonal |
100 ul |
EUR 369.6 |
PD-L1 Rabbit pAb |
A1645-200ul |
Abclonal |
200 ul |
EUR 550.8 |
PD-L1 Rabbit pAb |
A1645-20ul |
Abclonal |
20 ul |
EUR 219.6 |
PD-L1 Rabbit pAb |
A1645-50ul |
Abclonal |
50 ul |
EUR 267.6 |
PD-L1 Rabbit mAb |
A20270 |
Abclonal |
20 μL |
EUR 18 |
PD-L1 Rabbit mAb |
A20344 |
Abclonal |
20 μL |
EUR 18 |
PD-L1 (CD274) siRNA |
20-abx910978 |
Abbexa |
|
|
|
PD-L1 (CD274) siRNA |
20-abx910979 |
Abbexa |
|
|
|
PD-L1 Recombinant Protein |
91-293 |
ProSci |
0.05 mg |
EUR 405.6 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
PD-L1 Recombinant Protein |
92-486 |
ProSci |
0.05 mg |
EUR 374.1 |
Description: Mouse Programmed cell death 1 ligand 1(Cd274,PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
PD-L1 Recombinant Protein |
92-487 |
ProSci |
0.05 mg |
EUR 374.1 |
Description: Mouse Programmed cell death 1 ligand 1(Cd274,PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance. |
PD-L1 Recombinant Protein |
92-599 |
ProSci |
0.05 mg |
EUR 437.1 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
PD-L1 Recombinant Protein |
92-625 |
ProSci |
0.05 mg |
EUR 437.1 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
PD-L1 Recombinant Protein |
92-671 |
ProSci |
0.05 mg |
EUR 437.1 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers. |
PD-L1 Recombinant Protein |
96-937 |
ProSci |
0.1 mg |
EUR 619.8 |
Description: Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. |
PD-L1 Recombinant Protein |
97-020 |
ProSci |
0.1 mg |
EUR 714.3 |
Description: Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. |
PD-L1 Blocking Peptide |
20-abx161326 |
Abbexa |
|
|
|
B7-H1/PD-L1 |
E21-315 |
EnoGene |
10ug |
EUR 411.6 |
PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody |
DL21659F-20Tests |
DL Develop |
20Tests |
EUR 177.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody |
DL21659F-50Tests |
DL Develop |
50Tests |
EUR 237.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody |
DL21662F-25ug |
DL Develop |
25μg |
EUR 230 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE/Cyanine5.5 Anti-Mouse CD274/PD-L1 Antibody |
DL21662F-50ug |
DL Develop |
50μg |
EUR 357.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
PE/Cyanine5 Anti-Human CD274/PD-L1 Antibody |
DL21669F-20Tests |
DL Develop |
20Tests |
EUR 237.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
PE/Cyanine5 Anti-Human CD274/PD-L1 Antibody |
DL21669F-50Tests |
DL Develop |
50Tests |
EUR 335 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
PE/Cyanine7 Anti-Human CD274/PD-L1 Antibody |
DL21670F-20Tests |
DL Develop |
20Tests |
EUR 237.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
PE/Cyanine7 Anti-Human CD274/PD-L1 Antibody |
DL21670F-50Tests |
DL Develop |
50Tests |
EUR 335 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Mouse Anti-Human CD274 (PD-L1) mAbConjugated Antibody |
CCM025 |
SAB |
100ul |
EUR 476.4 |
Anti-PD-L1-Fab Avi-Tag, Biotin-Labeled |
11032 |
BPS Bioscience |
100 µg |
EUR 510 |
Description: PD-L1 Neutralizing Antibody FAB fragment, recombinant humanized monoclonal, recognizing the extracellular domain of human PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody FAB has been shown to cross-react with mouse PD-L1. No other species have been tested. |
PD-1:PD-L1 Homogeneous Assay Kit |
72014 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1:PD-L1 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L1. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L1 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts. |
PD-1:PD-L1 TR-FRET Assay |
72032 |
BPS Bioscience |
96 rxns. |
EUR 745 |
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 96 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader. |
PD-1:PD-L1 TR-FRET Assay |
72038 |
BPS Bioscience |
384 rxns. |
EUR 845 |
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader. |
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (HRP) |
20-abx319446 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (FITC) |
20-abx319447 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (Biotin) |
20-abx319448 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody |
A64216 |
EpiGentek |
-
EUR 684.66
-
EUR 117.70
-
EUR 302.50
-
EUR 423.50
|
- 100 µg
- 20 ul
- 50 ul
- 100 ul
|
PD-L1 Antibody / B7-H1 / CD274 |
F55054-0.1ML |
NSJ Bioreagents |
0.1ml |
EUR 339.15 |
Description: As a ligand for the inhibitory receptor PDCD1/PD-1, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response. [UniProt] |
PD-L1 Antibody / B7-H1 / CD274 |
R32479 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: Programmed death-ligand 1 (PD-L1), also known as CD274 or B7-H1, is a protein that in humans is encoded by the CD274 gene. It is mapped to 9p24.1. PD-L1 is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. It has been concluded that upregulation of PD-L1 on tumor MDCs downregulates T-cell immunity and that PD-L1 blockade may represent an approach for cancer immunotherapy. Additionally, PD-L1 can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. What’s more, it has been found that PD1/PDL1 pathway may be a good target for restoring antitumor immunity in ovarian cancer. |
PD-L1 Antibody / B7-H1 / CD274 |
R32579 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: B7 Homolog 1 (B7-H1), also known as CD274 or PD-L1, is a protein that in humans is encoded by the CD274 gene. It is mapped to 9p24.1. B7-H1 is a 40kDa type 1 transmembrane protein that has been speculated to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. It has been concluded that upregulation of B7-H1 on tumor MDCs downregulates T-cell immunity and that B7-H1 blockade may represent an approach for cancer immunotherapy. Additionally, B7-H1 can provide positive costimulatory signals for innate and adaptive immunity and for protection against intracellular bacterial infection. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
V9155SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955BTN |
NSJ Bioreagents |
500 ul |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955PE-100T |
NSJ Bioreagents |
100 Tests |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V3955SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V7822-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7822-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7822SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7823SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7974SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V7988SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8009SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8067SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8598SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8640SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
PD-L1 Antibody / B7-H1 / CD274 |
V8641SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system. |
anti-PD-L1 VHH antibody (Alexa Fluor® 647) |
JOT0002-5-1 |
Jotbody |
each |
Ask for price |
anti-PD-L1 VHH antibody (Alexa Fluor® 488) |
JOT0002-5-2 |
Jotbody |
each |
Ask for price |
anti-PD-L1 VHH antibody (Alexa Fluor® 568) |
JOT0002-5-3 |
Jotbody |
each |
Ask for price |
Mouse PD-L1 Antibody (Biotin Conjugate) |
32903-05121 |
AssayPro |
150 ug |
EUR 442.8 |
Anti-CD274/ PD-L1 Antibody [10F.9G2], PE-25ug |
QAB95-PE-25ug |
EnQuireBio |
25ug |
EUR 147.6 |
Anti-CD274/ PD-L1 Antibody [10F.9G2], PE-100ug |
QAB95-PE-100ug |
EnQuireBio |
100ug |
EUR 259.2 |
AF/LE Purified Anti-Mouse CD274/PD-L1 Antibody |
DL21654F-500ug |
DL Develop |
500μg |
EUR 507.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
AF/LE Purified Anti-Mouse CD274/PD-L1 Antibody |
DL21654F-50ug |
DL Develop |
50μg |
EUR 222.5 |
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production. |
AF/LE Purified Anti-Human CD274/PD-L1 Antibody |
DL21663F-500ug |
DL Develop |
500μg |
EUR 732.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
AF/LE Purified Anti-Human CD274/PD-L1 Antibody |
DL21663F-50ug |
DL Develop |
50μg |
EUR 252.5 |
Description: CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells. |
Anti-PD-L1 (CD274) (B7-H1), Rabbit Monoclonal Antibody |
A1824-50 |
Biovision |
each |
Ask for price |
Mouse Anti-PD-L1 IgG Monoclonal Antibody, Clone 3A9F12 |
7122 |
Chondrex |
1 mg/ml x 0.1 ml |
EUR 406.26 |
Description: Mouse Anti-PD-L1 IgG Monoclonal Antibody |
Anti-CD274/ PD-L1 Antibody [10F.9G2], Unconjugated-100ug |
QAB95-100ug |
EnQuireBio |
100ug |
EUR 229.2 |
Mouse Anti-Human PD-L1 monoclonal antibody, clone JID522 |
CABT-L2928-100uL500uL |
Creative Diagnostics |
100 uL, 500 uL |
EUR 602.4 |
PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit |
72028 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit is designed to measure_x000D_the inhibition of PD-1 binding to PD-L1. The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit_x000D_comes in a convenient AlphaLISA® format with purified biotinylated PD-1, FLAG-tagged PD-L1,_x000D_and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a_x000D_microtiter plate are required. First, a sample containing biotinylated PD-1 and an inhibitor of_x000D_choice is incubated with the FLAG-tagged PD-L1 for 60 minutes. Next, acceptor beads are_x000D_added, then donor beads, followed by reading the Alpha-counts. |
PD-L1 Fc Recombinant Protein |
40-696 |
ProSci |
20 ug |
EUR 311.1 |
Description: Programmed death-ligand 1 (PD-L1), or B7-H1, is a transmembrane, co-stimulatory ligand of programmed cell death protein 1 (PD-1) that, along with B7-1 and B7-2, belongs to the B7 family and immunoglobulin superfamily. Though more notably expressed on activated T cells, B cells, myeloid cells, and a subset of thymocytes, PD-L1 is also expressed constitutively by nonlymphoid, parenchymal organs, including the heart, placenta, skeletal muscle, and lung; with the marked exception of the small intestine. As a member of the B7 family, PD-L1 plays a principal role in immunity: suppressing immune response against autoantigens and tumors, maintaining T cell homeostasis, maintaining peripheral immune tolerance, and regulating T-cell-mediated cytokine secretion. Unlike B7-1 and B7-2, PD-L1 has not been shown to influence immunity through interaction with CD28, CTLA-4 or ICOS, but rather through interaction with PD-1, a weak structural homolog of CTLA-4 that belongs to the same superfamily. Involvement of PD-1 suggests an inhibitory function during T cell activation; however, evidence has demonstrated PD-L1’s conflicting responsibility for both the stimulation and inhibition of T-cell-mediated cytokine synthesis. While T cell co-stimulation with PD-L1 induces proliferation and the secretion of IL-10 and IFN-γ, muscle cell expression of PD-L1 has been shown to inhibit function of CD4 and CD8 T cells by down-regulating cytokine secretion and the expression of T cell activation markers. Augmented expression of PD-L1 has been linked to the inhibition of antitumor immune response in cancer, and the up-regulation of IL-10 production in HIV-infection, resulting in increased susceptibility of antigen-specific T cells to apoptosis. CHO cell-derived Recombinant Human PD-L1 Fc is a glycosylated, disulfide-linked homodimer of 906 amino acid residues whose monomer consists of the 220-amino-acid length extracellular portion of PD-L1 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of CHO cell-derived Recombinant Human PD-L1 Fc is 102.6 kDa, however, due to glycosylation, it migrates at an apparent molecular weight of approximately 160-170 kDa by SDS-PAGE analysis under non-reducing conditions. |
PD-L1 /CD274, Human Recombinant |
P1023-10 |
Biovision |
each |
EUR 301.2 |
PD-L1 /CD274, Human Recombinant |
P1023-50 |
Biovision |
each |
EUR 823.2 |
PD-L1/B7-H1/CD274 |
E21-J88 |
EnoGene |
10ug |
EUR 411.6 |
Ribosome-inactivating protein PD-L1/PD-L2 Antibody, HRP conjugated |
1-CSB-PA306294LB01PJJ |
Cusabio |
|
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is HRP conjugated. Tested in the following application: ELISA |
Ribosome-inactivating protein PD-L1/PD-L2 Antibody, FITC conjugated |
1-CSB-PA306294LC01PJJ |
Cusabio |
|
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is FITC conjugated. Tested in the following application: ELISA |
Ribosome-inactivating protein PD-L1/PD-L2 Antibody, Biotin conjugated |
1-CSB-PA306294LD01PJJ |
Cusabio |
|
|
|
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Biotin conjugated. Tested in the following application: ELISA |
Anti-CD274/ PD-L1 Antibody [10F.9G2], Qfluor 630-100ug |
QAB95-QF630-100ug |
EnQuireBio |
100ug |
EUR 310.8 |
Polyclonal B7-H1 / PD-L1 / CD274 Antibody |
APR03374G |
Leading Biology |
0.05ml |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human B7-H1 / PD-L1 / CD274 . This antibody is tested and proven to work in the following applications: |
PD-1[Biotinylated]: PD-L1 Inhibitor Screening Assay Kit |
79523 |
BPS Bioscience |
384 rxns. |
EUR 1070 |
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and is exploited by both tumors and viruses. The PD-1[Biotinylated]: PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. This kit comes in a convenient 384-well format with biotin-labeled PD-1, purified PD-L1, streptavidin-labeled HRP, and assay buffer for 400 binding reactions. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 384-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit |
72003 |
BPS Bioscience |
96 rxns. |
EUR 1235 |
Description: The PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-L1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on a 96-well plate. Next, PD-L1 is incubated with PD-1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit |
72005 |
BPS Bioscience |
96 rxns. |
EUR 840 |
Description: The PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader. |
Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 |
1-CSB-EP306294PJJ |
Cusabio |
-
EUR 733.20
-
EUR 370.80
-
EUR 2192.40
-
EUR 1126.80
-
EUR 1461.60
-
EUR 476.40
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
Description: Recombinant Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 expressed in E.coli |
Mouse PD-L1 AssayLite Antibody (RPE Conjugate) |
32903-05151 |
AssayPro |
150 ug |
EUR 513.6 |
Mouse PD-L1 AssayLite Antibody (APC Conjugate) |
32903-05161 |
AssayPro |
150 ug |
EUR 513.6 |
Antibodies didn’t have an effect on the motor efficiency or anxiousness scores in mice. These findings counsel that neuronal antibodies concentrating on completely different epitopes throughout the NMDA receptor could end in the same seizure phenotype.